Educational guide
Triptorelin Acetate Dosage Protocol - Peptide Dosages
Triptorelin Acetate (2 mg) Dosage Protocol A potent GnRH-agonist decapeptide (the drug Decapeptyl / Trelstar) that first stimulates, then shuts down, the entire reproductive hormone axis. Research-use-only reference — not medical advice and not a dosing recomm
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
Triptorelin Acetate (2 mg) Dosage Protocol
A potent GnRH-agonist decapeptide (the drug Decapeptyl / Trelstar) that first stimulates, then shuts down, the entire reproductive hormone axis. Research-use-only reference — not medical advice and not a dosing recommendation.
Why Triptorelin draws research interest
These are the directions researchers and the peptide community most often explore Triptorelin for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.
It stimulates first, then suppresses — the flare is the catch
The counterintuitive thing about GnRH agonists like triptorelin is that they begin by doing the opposite of their therapeutic goal. Continuous strong stimulation of the pituitary GnRH receptor initially <em>increases</em> LH and FSH release, driving a transient surge in testosterone (in men) or estrogen (in women) over roughly the first one to two weeks. Only after that does the receptor desensitize and down-regulate, at which point gonadotropins and sex hormones fall to castrate or menopausal levels. In prostate cancer this early “flare” can briefly worsen the disease — bone pain or urinary obstruction — which is exactly why clinicians often add an antiandrogen for the first weeks. That biphasic behavior is central to understanding the drug and is one more reason it is not a casual compound.
The approved product is a depot, not a vial you reconstitute
Nearly all clinical triptorelin is given as sustained-release microsphere depots designed to release the peptide slowly over one, three or six months from a single intramuscular injection. That controlled, long-duration release is the whole point of the formulation — it keeps the GnRH receptor continuously occupied so suppression is maintained. A plain 2 mg research vial of triptorelin acetate is the immediate-release peptide, which behaves completely differently from a depot. Treating a research vial as if it were the approved medicine misunderstands both the pharmacology and the product, and there is no validated self-injection regimen for it.
A powerful, whole-axis endocrine switch
Triptorelin does not nudge one hormone; it takes the entire hypothalamic–pituitary–gonadal axis offline. In men that means medical castration — very low testosterone, hot flushes, loss of libido and erectile function, and, over months, bone-density loss. In women it induces a menopause-like state with the corresponding effects. These are profound, system-wide changes that are useful when a clinician deliberately wants them for a defined condition, and are risky and inappropriate when self-induced. The honest framing is that this is a specialist hormonal therapy, not something to experiment with.
Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.
Mix & measure Triptorelin · 2 mg
Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers.
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →
A long-acting GnRH agonist that over-stimulates the pituitary GnRH receptor. The first days bring a surge of LH, FSH and sex hormones (the "flare"); continued exposure then desensitizes and down-regulates the receptor, collapsing LH/FSH and driving testosterone or estrogen down to castrate/menopausal levels.
An approved prescription hormone (Decapeptyl, Trelstar, Diphereline) delivered as long-acting depot microspheres for prostate cancer, endometriosis, uterine fibroids and central precocious puberty. It is used to induce a controlled, reversible medical castration under specialist supervision, not as a wellness or performance peptide.
Clinical trials establish that triptorelin depots reliably suppress testosterone to castrate levels in prostate cancer, with a well-characterized early testosterone flare that can transiently worsen hormone-driven disease unless covered. The mechanism and suppression are well documented; none of that evidence supports self-administering a research vial.
Quickstart Highlights
Triptorelin is a synthetic decapeptide agonist of gonadotropin-releasing hormone (GnRH) — a modified version of the body’s own GnRH that binds the pituitary GnRH receptor far more strongly and for far longer. It is the active ingredient in the approved medicines Decapeptyl, Trelstar and Diphereline, used to switch off sex-hormone production in conditions such as prostate cancer, endometriosis and central precocious puberty[1][2].
This page is an educational reference on what triptorelin is, the unusual two-phase way it works, and what the research shows. It is not medical advice and not a protocol to self-administer the peptide. Two facts matter up front. First, triptorelin does not gently “boost” hormones — it produces an initial surge and then a deep, sustained suppression of the whole reproductive axis[2]. Second, the approved products are long-acting depot injections (monthly, 3-monthly or 6-monthly microspheres), not a simple reconstituted vial — so a 2 mg research vial is not the approved medicine.
A GnRH-agonist decapeptide (the drug Decapeptyl / Trelstar) that binds the pituitary GnRH receptor and, after an initial surge, suppresses LH, FSH and sex-hormone output[2].
Biphasic: a flare (transient rise in testosterone/estrogen) for the first ~1–2 weeks, then down-regulation to castrate-level suppression[1][2].
FDA-approved as depot triptorelin (Trelstar/Decapeptyl). A grey-market 2 mg research vial is not the approved long-acting product and is not quality-assured.
Robust human clinical data for the approved depot in prostate cancer and other indications[4]. That evidence belongs to the depot formulations under medical care, not to self-dosed research vials.